Delving into the Latest Updates on Honeybrains Biotech with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

关联

1

项与 Honeybrains Biotech 相关的药物

HB-1

靶点-

作用机制-

在研机构

Honeybrains Biotech

原研机构

Honeybrains Biotech

在研适应症

行为障碍 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

2

项与 Honeybrains Biotech 相关的临床试验

NCT06483789 / Not yet recruiting临床2期

Efficacy and Safety of HB-1 for Panic Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo and two monotherapies, in male and female adult patients aged 18 to 65 years, inclusive, with Panic Disorder.

开始日期2024-08-01

申办/合作机构

Honeybrains Biotech

NCT05071430 / Completed临床2期

Safety and Efficacy of HB-1 for Panic Disorder: A Multicenter, Randomized, Double Blind, Placebo-Controlled Trial

The purpose of this study is to determine the safety and efficacy of HB-1 versus placebo in male and female adult patients aged 18 to 60 years, inclusive, with Panic Disorder.

开始日期2022-02-03

申办/合作机构

Honeybrains Biotech

[+1]

100 项与 Honeybrains Biotech 相关的临床结果

登录后查看更多信息

0 项与 Honeybrains Biotech 相关的专利（医药）

登录后查看更多信息

100 项与 Honeybrains Biotech 相关的药物交易

登录后查看更多信息

100 项与 Honeybrains Biotech 相关的转化医学

登录后查看更多信息